Supreme Court slams ‘extortion’ in drug pricing; calls for Jan Aushadhi expansion

23 Sep Supreme Court slams ‘extortion’ in drug pricing; calls for Jan Aushadhi expansion

✎ The Supreme Court’s observation underscores the critical need for the NPPA to enforce strict price controls on all essential medicines, ensuring that MRPs reflect fair PTRs and that Jan Aushadhi Kendras are expanded to bridge the…

Subject Relevance — Where This Topic Fits

• GS Paper II — Governance, Transparency and Accountability  |  GS Paper III — Issues relating to Intellectual Property Rights, Health, and Pricing
• Prelims: Drug Price Control Order (DPCO), 2013, National Pharmaceutical Pricing Authority (NPPA), Jan Aushadhi Kendras, Essential Medicines List, Market-Based Pricing (MBP), Price to Retailer (PTR), Maximum Retail Price (MRP), Patent Act, 1970, Compulsory Licensing
• Essay: The role of judicial activism in ensuring equitable access to essential goods, Balancing innovation incentives with public health affordability in pharmaceuticals

Quick Revision: The Supreme Court’s observation underscores the critical need for the NPPA to enforce strict price controls on all essential medicines, ensuring that MRPs reflect fair PTRs and that Jan Aushadhi Kendras are expanded to bridge the affordability gap.

Why is this in the news?

The Supreme Court of India, while hearing Public Interest Litigations (PILs) on the exorbitant pricing of essential medicines, observed that the pricing disparity between the manufacturer’s price to retailers and the Maximum Retail Price (MRP) charged to patients constitutes a form of ‘extortion’ or ‘dacoity in broad daylight.’ The bench highlighted the lack of regulatory oversight and urged the inclusion of all medicines under price control mechanisms, suggesting expansion of the Jan Aushadhi Kendras network to ensure affordable access to critical drugs.

Background

• The pricing of pharmaceuticals in India is governed by the Drug Price Control Order (DPCO), which empowers the National Pharmaceutical Pricing Authority (NPPA) to regulate prices of essential drugs under the Essential Medicines List (EML).
• The DPCO operates under the Essential Commodities Act, 1955, and employs a Market-Based Pricing (MBP) approach, capping the ceiling price of scheduled formulations based on market data.
• Despite regulatory mechanisms, studies have consistently shown significant price disparities between the price to retailers (PTR) and the MRP, particularly for life-saving drugs such as cancer medications and antibiotics.
• The Jan Aushadhi Kendras initiative, launched in 2008, aims to provide quality generic medicines at affordable prices through dedicated outlets, though its reach remains limited compared to the demand.
• Public interest litigations have repeatedly highlighted the issue of overpricing, with petitions citing instances where MRPs exceed PTRs by 10-16 times, placing undue financial burden on patients.
• The Supreme Court’s observations reflect growing judicial scrutiny of regulatory failures in ensuring equitable access to essential medicines, reinforcing the need for systemic reforms.

What is Drug Pricing Regulation in India?

• The Drug Price Control Order (DPCO) is a legal instrument issued under the Essential Commodities Act, 1955, to regulate the prices of essential and life-saving drugs in India.
• The National Pharmaceutical Pricing Authority (NPPA), a statutory body under the Ministry of Chemicals and Fertilizers, is responsible for implementing the DPCO, including price fixation, monitoring, and enforcement.
• The Essential Medicines List (EML) is a core component of the DPCO, comprising drugs identified as essential for addressing priority health concerns; pricing regulations apply primarily to these formulations.
• Market-Based Pricing (MBP) is the methodology used by the NPPA to determine ceiling prices, based on data from market sales, ensuring prices remain within reasonable limits while accounting for manufacturer costs and profit margins.
• The Maximum Retail Price (MRP) is the legally mandated upper limit for the sale of a drug to consumers, determined by the manufacturer and printed on the packaging; retailers are prohibited from exceeding this price.
• The Price to Retailer (PTR) is the cost at which a manufacturer sells a drug to a retailer, which forms the basis for calculating the MRP under the MBP framework.
• Jan Aushadhi Kendras are government-sponsored generic medicine stores that aim to provide affordable alternatives to branded drugs, particularly for low-income and rural populations.
• The DPCO also includes provisions for monitoring and penalizing overpricing, though enforcement remains a challenge due to market complexities and regulatory gaps.

Key Features

Feature	Significance
Exorbitant drug pricing	Undermines affordability of essential medicines, exacerbates financial distress among patients, particularly those with chronic or life-threatening conditions.
Price disparity between MRP and PTR	Highlights systemic exploitation where manufacturers supply drugs at low prices to retailers but allow inflated MRPs, enabling profiteering.
Supreme Court’s observation of ‘extortion’	Emphasises judicial recognition of unethical pricing practices and calls for regulatory intervention to protect public health.
Suggestion to bring all medicines under price control	Proposes expanding the scope of the National Pharmaceutical Pricing Authority (NPPA) to regulate a broader range of drugs, ensuring equitable access.
Mention of Jan Aushadhi Kendras	Reinforces the role of government-run generic medicine outlets as a viable alternative to curb profiteering in the pharmaceutical sector.

Why it Matters

Economic

• Exorbitant drug pricing contributes to out-of-pocket expenditure, pushing households into debt or poverty, particularly in low-income groups.
• Profit-driven pricing in the pharmaceutical sector distorts market efficiency and discourages investment in public health infrastructure.
• Inflated drug prices reduce the purchasing power of consumers, impacting overall economic welfare and productivity.

Health Governance

• Judicial intervention underscores the failure of existing regulatory mechanisms to curb unethical pricing practices in the pharmaceutical industry.
• The case highlights the need for stronger enforcement of the Drugs (Prices Control) Order, 2013, to ensure compliance with price ceilings.
• Expanding the ambit of price control to all essential medicines could align India’s drug pricing policy with global best practices in public health governance.

Social Justice

• Affordable access to medicines is a fundamental component of the right to health, as recognised in international human rights frameworks and India’s constitutional obligations.
• Marginalised and economically weaker sections bear the brunt of drug price inflation, exacerbating health inequities.
• The Supreme Court’s stance reinforces the state’s duty to protect citizens from exploitation in critical sectors like healthcare.

Challenges

1. Regulatory Gaps in Drug Pricing

• The Drugs (Prices Control) Order, 2013, excludes several essential drugs from price regulation, allowing manufacturers to set arbitrary MRPs.
• Lack of stringent monitoring mechanisms enables retailers to exploit loopholes in MRP regulations, leading to price inflation.
• Weak enforcement by the National Pharmaceutical Pricing Authority (NPPA) fails to deter unethical pricing practices.

UPSC Link: GS2: Health Governance – Regulatory Bodies

2. Profit-Driven Pharmaceutical Industry

• Pharmaceutical companies prioritise profit margins over public health, leading to inflated prices for life-saving drugs.
• Patent monopolies and lack of generic competition in certain segments enable price gouging, particularly for patented or niche drugs.
• Retailers collude with manufacturers to maintain high MRPs, exploiting consumer ignorance and urgency in purchasing medicines.

UPSC Link: GS3: Indian Economy – Industrial Policy

3. Financial Burden on Patients

• High drug prices force patients to liquidate assets or forego treatment, worsening health outcomes and perpetuating cycles of poverty.
• Chronic patients, such as those undergoing cancer treatment, face disproportionate financial strain due to prolonged medication needs.
• Out-of-pocket expenditure on medicines constitutes a significant portion of India’s total healthcare spending, straining household budgets.

UPSC Link: GS2: Health – Public Health Challenges

4. Public Health Infrastructure Deficits

• Inadequate availability of generic medicines in government-run outlets (e.g., Jan Aushadhi Kendras) limits alternatives to high-cost branded drugs.
• Urban-rural disparities in access to affordable medicines exacerbate health inequities, particularly in remote areas.
• Limited awareness among consumers about price regulations and their rights contributes to exploitation by retailers and manufacturers.

UPSC Link: GS2: Health – Health Infrastructure

Challenges — UPSC Perspective

Issue	Concern
Exclusion of essential drugs from price control	Allows manufacturers to set arbitrary MRPs, leading to profiteering.
Weak enforcement by NPPA	Fails to deter unethical pricing practices due to inadequate monitoring and penalties.
Collusion between retailers and manufacturers	Enables exploitation of consumers through inflated MRPs and artificial scarcity.
Limited availability of generic medicines	Restricts alternatives to high-cost branded drugs, particularly in rural areas.
Lack of consumer awareness	Prevents patients from identifying and reporting price violations, perpetuating exploitation.

Government Initiatives — Must-Memorise for Prelims

• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

Way Forward

• Strengthen the enforcement mechanisms of the National Pharmaceutical Pricing Authority (NPPA) to ensure strict compliance with price ceilings.
• Expand the scope of the Drugs (Prices Control) Order, 2013, to include all essential medicines under price regulation.
• Enhance the distribution network of Jan Aushadhi Kendras to improve access to affordable generic medicines across urban and rural areas.
• Conduct periodic audits of pharmaceutical companies to identify and penalise instances of price gouging and collusion.
• Launch public awareness campaigns to educate consumers about their rights under drug pricing regulations and how to report violations.
• Encourage research and development of generic alternatives to patented drugs to foster competition and reduce prices.
• Collaborate with state governments to integrate Jan Aushadhi Kendras with primary healthcare centres for seamless service delivery.

UPSC Value Addition

Prelims Practice Questions

Q1. Consider the following statements regarding the National Pharmaceutical Pricing Authority (NPPA):
1. It is a statutory body established under the Essential Commodities Act, 1955.
2. It regulates the prices of all drugs in India.
3. It monitors the availability of drugs in the market and takes action against overcharging.
4. It is empowered to fix the ceiling prices of scheduled formulations.

How many of the above statements are correct?

1. Only one
2. Only two
3. Only three
4. All four

Answer: Only three — Statements 3 and 4 are correct. Statement 1 is incorrect because NPPA was established under the Drugs (Prices Control) Order, 1995, not the Essential Commodities Act. Statement 2 is incorrect as NPPA does not regulate the prices of all drugs, only those included in the scheduled formulations list.

Q2. Assertion (A): The Supreme Court of India has recently directed the government to bring all medicines under the price control mechanism.

Reason (R): The court observed that the exorbitant pricing of drugs amounts to extortion and violates the right to health of citizens.

Options:
A. Both A and R are true, and R is the correct explanation of A.
B. Both A and R are true, but R is not the correct explanation of A.
C. A is true, but R is false.
D. A is false, but R is true.

Answer: ? — Both the assertion and reason are true, and the reason correctly explains the assertion. The Supreme Court’s observations on drug pricing and its directive to bring all medicines under price control are directly linked to the violation of the right to health.

Q3. Match the following schemes/policies with their respective objectives:

Column I (Scheme/Policy) | Column II (Objective)
————————-|————————
A. Jan Aushadhi Kendras | 1. To provide affordable medicines through dedicated stores
B. AMRIT Scheme | 2. To regulate the prices of essential drugs
C. National List of Essential Medicines (NLEM) | 3. To provide affordable cancer and cardiac drugs
D. Drugs (Prices Control) Order, 2013 | 4. To identify and promote the use of essential medicines

Options:
A. A-1, B-3, C-4, D-2
B. A-2, B-1, C-3, D-4
C. A-3, B-2, C-1, D-4
D. A-4, B-3, C-2, D-1

Answer: ? — The correct matches are: A-1 (Jan Aushadhi Kendras provide affordable medicines), B-3 (AMRIT Scheme focuses on affordable cancer and cardiac drugs), C-4 (NLEM identifies essential medicines), and D-2 (Drugs (Prices Control) Order regulates prices of essential drugs).

Mains Practice Question

✍ The Supreme Court of India has recently observed that the exorbitant pricing of drugs in India amounts to ‘extortion’ and violates the fundamental right to health. Critically examine the regulatory framework governing drug pricing in India, highlighting the role of the National Pharmaceutical Pricing Authority (NPPA) and the challenges in ensuring affordable access to essential medicines. Also, discuss the feasibility and implications of bringing all medicines under the price control mechanism. (15 Marks)

Approach: MODEL-ANSWER SKELETON:

1. **Introduction (2 Marks)**:
– Briefly introduce the Supreme Court’s observations and the context of drug pricing in India.
– Mention the right to health as a fundamental right under Article 21 of the Constitution.

2. **Regulatory Framework for Drug Pricing (5 Marks)**:
– **Drugs (Prices Control) Order (DPCO)**: Explain its evolution from DPCO 1995 to DPCO 2013, and its objective to regulate prices of essential drugs.
– **National Pharmaceutical Pricing Authority (NPPA)**: Discuss its role, powers, and limitations under the DPCO.
– **Essential Commodities Act, 1955**: Explain its relevance in regulating drug prices during emergencies.
– **National List of Essential Medicines (NLEM)**: Discuss its role in identifying essential drugs for price control.

3. **Challenges in Ensuring Affordable Access (4 Marks)**:
– **Market Dynamics**: Discuss the influence of pharmaceutical companies, patented drugs, and market monopolies.
– **Implementation Gaps**: Highlight issues like non-compliance, lack of transparency, and loopholes in the DPCO.
– **Judicial Interventions**: Cite recent Supreme Court judgments (e.g., on MRP vs. PTR disparities) and their impact.
– **Public Health Infrastructure**: Discuss the role of Jan Aushadhi Kendras and AMRIT Scheme in bridging the affordability gap.

4. **Feasibility and Implications of Universal Price Control (3 Marks)**:
– **Arguments for Universal Control**: Discuss the need to bring all medicines under price control to prevent exploitation.
– **Arguments Against Universal Control**: Highlight concerns like reduced innovation, industry resistance, and administrative burden.
– **Balanced Approach**: Suggest a phased inclusion of medicines under price control, with differential pricing for patented drugs.

5. **Conclusion (1 Mark)**:
– Summarize the need for a robust regulatory framework to balance affordability and innovation in the pharmaceutical sector.

Source: Times of India

---

Generated by AanyaAi for educational purpose.

---

Related guides on our sites

• Best PSIR optional coaching for upsc
• Best PSIR optional teacher for upsc
• Best teacher of PSIR optional for upsc
• Best PSIR optional coaching in delhi for UPSC